Optive Research Teams with Microsoft, HP, and AMD for High Performance Drug Discovery
Companies to Demonstrate Discovery Informatics Solutions based on Windows Server 2003 Enterprise Edition for 64-bit Extended Systems on AMD Opteron™ Processor-Powered HP Clusters at Upcoming Supercomputing 2004 Event
AUSTIN, TX --
Optive Research, Inc., a life sciences software company providing innovative solutions for computer-assisted molecular discovery, today announced that it has expanded its existing alliances with Microsoft (NASDAQ: MSFT) and HP (NYSE: HPQ) and has initiated a relationship with AMD (NYSE: AMD) to provide additional High Performance Computing (HPC) platform options for its customers.
The companies will be demonstrating Optive’s Discovery Informatics products on a beta version of the Microsoft Windows Server 2003, Enterprise Edition for 64-bit Extended Systems operating system and HP DL145-based clusters powered by AMD Opteron™ processors at the Supercomputing 2004 event in Pittsburgh, PA this month.
“The performance of our Discovery Informatics products, including the popular Concord™ program for 3D chemical structure generation, on the Windows Server 2003 operating system with AMD Opteron processor-powered HP clusters has been impressive,” said Davin Potts, Ph.D., senior scientist with Optive Research. “Based on internal benchmarks, the OS is achieving at least platform parity with several flavors of Linux, and in some cases we are seeing as high as 50% faster performance when compared to Red Hat Enterprise Linux 3.0.”
Earlier this year, Microsoft confirmed that it expects to deliver the HPC version of the Windows Server 2003 operating system in the second half of 2005. Optive, who has also been working with Microsoft to develop a new version of its Benchware™ software for medicinal chemists, based on the .NET platform, is planning to add Windows Server 2003, Compute Cluster Edition to its list of supported Discovery Informatics platforms, which currently includes the IRIX and Linux operating systems.
“High performance computing is one of the fastest growing server workloads worldwide, with applications in many industry verticals to solve complex business, technical, and scientific problems,” said Kyril Faenov, director of HPC at Microsoft. “Our collaboration with Optive Research is helping Microsoft better understand the unique HPC requirements facing discovery scientists at many of the world’s leading pharmaceutical companies, ensuring that Windows Server 2003, Compute Cluster Edition, when launched, will meet the needs of the Life Science community.”
Optive will be demonstrating its Discovery Informatics products, along with HP and AMD, in the Microsoft booth # 1815 at Supercomputing 2004, in Pittsburgh November 8 – November 11th.
For more information about Windows Server 2003 and High Performance Computing at Microsoft, visit: http://www.microsoft.com/hpc
For more information about HP DL145 clusters, featuring the AMD Opteron processor, visit: http://h18004.www1.hp.com/products/servers/proliantdl145
About Optive Research, Inc
Optive Research develops, markets and supports life science software solutions that help companies engaged in molecular discovery research bring beneficial chemical compounds to market faster, while reducing overall cost. Optive’s novel software is designed for both computational chemists and experimental, “wet-lab” scientists, enabling them to reduce discovery cycle times and synthesize higher-quality lead compounds, thereby achieving more predictable discovery and development processes. Software developed by Optive Research is currently in use at almost every major pharmaceutical company and at hundreds of other research sites worldwide. More information about Optive Research is available at www.optive.com